A Glioblastoma Immunotherapy Modality based on Dendritic Cell Reprogramming In Vivo
| Reference number | |
| Coordinator | Lunds universitet - Institutionen för laboratoriemedicin |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - October 2025 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Important results from the project
The project aimed to revolutionize glioblastoma treatment by developing an immunotherapy modality based on in vivo dendritic cell reprogramming. During the course of the project, we successfully established proof-of-concept of a glioblastoma immunotherapy modality based on dendritic cell reprogramming in vivo in preclinical models of the disease, demonstrating its feasibility for one of the most aggressive tumor types in the human adult brain.
Expected long term effects
By achieving proof-of-concept for a gene therapy that treats glioblastoma through in vivo dendritic cell reprogramming, this project advanced cellular reprogramming as a viable treatment strategy for glioblastoma and virtually all cancer types. The knowledge generated will contribute to future clinical trials and support the development of precision therapies for high-grade brain tumors.
Approach and implementation
The project was implemented through a structured collaboration between Swedish and US teams, following an established work plan that included in vitro and in vivo mechanistic studies and evaluation of reprogramming efficiency in pre-clinical glioblastoma models. Coordination of resources and regular check-ins ensured alignment and project’s progression according to plan.